The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Main goals for treating patients with AL amyloidosis: achieving complete hematologic response
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, briefly discusses the main goals for treating patients with light chain (AL) amyloidosis, emphasizing the importance of achieving a complete hematologic response (CHR). Prof. Sanchorawala also comments on the value of measurable residual disease (MRD) assessment in these patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
